Q-omics provides the consensus-scored HOXD13 profile across patient tissues and cancer cell-line models. HOXD13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HOXD13 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, HOXD13 protein abundance shows 20,316 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where HOXD13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD13 survival associations across molecular data types. HOXD13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD13 RNA expression–survival associations across cancer types. High HOXD13 expression shows unfavorable associations in ACC, UVM, KIRP, MESO, THYM and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HOXD13 RNA expression.
This table summarizes HOXD13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for HOXD13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD13 shows lower tumor expression in PRAD and higher tumor expression in HNSC, KIRC, LUSC, UCEC and COAD. The HNSC box plot shows higher HOXD13 RNA expression in tumor versus normal tissue (log2 FC = +2.878, t-test p < 0.001).
This table shows molecular features associated with HOXD13 in patient tissues and cancer cell lines. In patient samples, HOXD13 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
